Companies · Biotechnology

Barosense Inc

REDWOOD CITY · Biotechnology

Diligence memoA one-page analyst read on Barosense Inc — recommendation, valuation, rhythm, risks.
$56.9M
Total raised · real
2
Rounds
0.9×
Latest step-up
Top 17%
Sector rank · raised
Series B
Latest stage · inferred · Thu Aug 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Barosense Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.32× the median modeled value of Series B Biotechnology companies in 2007–2009 (21 peers) — value vs value, same stage and era.
  • Within the normal band (132% of peer median) for its niche.
Dormant
  • Last raise 16.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Barosense Inc is one of 4291 Biotechnology companies tracked from REDWOOD CITY. By capital raised it ranks in the upper tier (ahead of 84% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries B · 2009-08-13 Raised $29M (real) Modeled valuation $1.2B (est)$29M$1.2BSeries B2009Series B · 2009-08-13 Raised $27M (real) Modeled valuation $1.1B (est)$27M$1.1BSeries B2009+$27MCumulative $57M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$29.5M · 2009
Series B extension$27.4M · 2009

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$1.2B
Base estimate est.
$59.0M
Conservative case
$4.5B
Upside case
$163.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.2B · 2009-08-132009Series B · modeled $1.1B · 2009-08-132009
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
16.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
16.9 yr
On record since
2009
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.9× above median
This company$56.9M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.6× above median
This company$27.4M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 18× above median
This company$1.2B
Sector median$64.2M

Raised more than 84% of sector peers (real $). Modeled value above 91% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 21.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)Ion Torrent Systems Inc · Series B Raised $59.9M · modeled $1.5B (est)PhotoThera Inc · Series B Raised $36.4M · modeled $1.4B (est)Taligen Therapeutics Inc · Series B Raised $62.1M · modeled $1.4B (est)Atritech Inc · Series B Raised $30.0M · modeled $1.2B (est)Palyon Medical Corp · Series B Raised $45.0M · modeled $952.5M (est)Pfenex Inc. · Series B Raised $24.0M · modeled $952.5M (est)Inhibitex, Inc. · Series B Raised $23.0M · modeled $912.9M (est)Coaxia Inc · Series B Raised $40.0M · modeled $893.0M (est)Avila Therapeutics Inc · Series B Raised $45.0M · modeled $893.0M (est)Lensx Lasers Inc · Series B Raised $22.4M · modeled $887.5M (est)Radiorx, Inc. · Series B Raised $47.7M · modeled $811.6M (est)Barosense Inc (this company) Raised $56.9M · modeled $1.2B (est)Barosense Inc
CompanyStageRaised · realValue · estvs peer med.
Ion Torrent Systems IncSeries B$59.9M$1.5B1.66×
PhotoThera IncSeries B$36.4M$1.4B1.63×
Taligen Therapeutics IncSeries B$62.1M$1.4B1.61×
Atritech IncSeries B$30.0M$1.2B1.34×
Barosense Inc this companySeries B$56.9M$1.2B1.32×
Palyon Medical CorpSeries B$45.0M$952.5M1.07×
Pfenex Inc.Series B$24.0M$952.5M1.07×
Inhibitex, Inc.Series B$23.0M$912.9M1.03×
Coaxia IncSeries B$40.0M$893.0M1.01×
Avila Therapeutics IncSeries B$45.0M$893.0M1.01×
Lensx Lasers IncSeries B$22.4M$887.5M1.00×
Radiorx, Inc.Series B$47.7M$811.6M0.91×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$29.5M2009-08-13$163.8M$1.2B90%
Series B$27.4M2009-08-13$152.3M$1.1B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$29.5M2009-08-13
    • First recorded raise — entered as Series B.
  2. Series B$27.4M2009-08-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
Modeled next raise
$27.4M
Modeled next size est.range $27.4M$43.9M
0.9×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Alan Levy6 other2009-08
Eric Linsley3 other2009-08
John Onopchenko3 other2009-08
Daniel J. Balbierz2009-08
Gregory A. Barrett2009-08
Richard Stack2009-08
Registry & provenance

Barosense Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1178038
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Gen1E Lifesciences Inc.BiotechnologySeries B$22.5M$22.5Mnetwork1 shared operator · same sector · same stage
Tenex Health, Inc.BiotechnologySeries B$57.4M$1.2Bsame sector · same stage
Tracon Pharmaceuticals, Inc.BiotechnologySeries B$57.7M$1.5Bsame sector · same stage
Valeritas Holdings Inc.BiotechnologySeries B$58.2M$1.3Bsame sector · same stage
Argos Therapeutics IncBiotechnologySeries B$55.4M$873.5Msame sector · same stage
Petra Pharma CorpBiotechnologySeries B$58.8M$1.1Bsame sector · same stage
CONTRAFECT CorpBiotechnologySeries B$58.8M$793.8Msame sector · same stage
Stratos Genomics Inc.BiotechnologySeries B$58.9M$800.0Msame sector · same stage
Frequently asked
How much funding has Barosense Inc raised?
Barosense Inc has raised approximately $56.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Barosense Inc's estimated valuation?
Provath's modeled valuation for Barosense Inc is approximately $1.2B (modeled range $59.0M–$4.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Barosense Inc at?
Barosense Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Aug 13.
What does Barosense Inc do and where is it based?
Barosense Inc operates in the Biotechnology sector, based in REDWOOD CITY.
Explore related

See where Barosense Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Barosense Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.